AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33138835
Drug: Early BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early BC on treatment post-surgery (Group 1, 89 patients)
Trial: 33138835
Drug: Early BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early BC after completion of adjuvant treatment (Group 2, 108 patients)
Trial: 33138835
Drug: Metastatic BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastatic BC treatment (Group 3, 102 patients)
Trial: 33138848
Drug: Mouthwash containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash containing antivirals (β-cyclodextrin and Citrox®)
Trial: 33139055
Drug: Volasertib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib monotherapy (Cycle 2)
Trial: 33139139
Drug: NVX-CoV2373 vaccine
RxNorm normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 vaccine with Matrix-M™ adjuvant
Trial: 33139266
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity
Trial: 33140664
Drug: Parsaclisib (INCB050465),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib (INCB050465), a highly selective PI3Kδ inhibitor, used as monotherapy.
Trial: 33141094
Drug: Remote titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote titration facilitated by a smartphone-based telemonitoring system
Trial: 33141101
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual group (n=10)
Trial: 33142850
Drug: Motor program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor program activating therapy
Trial: 33145266
Drug: Apatinib, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib, 500 mg once daily, until disease progression, unacceptable toxicity, consent withdrawal, or death.
Trial: 33145616
Drug: Berzosertib (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berzosertib (intravenous infusion)
Trial: 33145809
Drug: Low-Dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose CT (LDCT) imaging for osteoporosis screening
Trial: 33146624
Drug: Standardized discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized discharge prescription forms with 90-day prescriptions and 3 repeats for recommended cardiac medication classes, in combination with education
Trial: 33146624
Drug: Longer (>60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer (>60 days) versus shorter prescription durations
Trial: 33146628
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccine against Streptococcus pneumoniae
Trial: 33146741
Drug: Cemiplimab 250
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 250 mg every 3 weeks
Trial: 33146953
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment on HT-7 for 5 weeks
Trial: 33147119
Drug: Sequential imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential imaging with dual tracers
Trial: 33147119
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of PET tracers
Trial: 33147283
Drug: 3D regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D regimen treatment
Trial: 33147613
Drug: RA patients
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RA patients with MTX only or with other medications
Trial: 33148235
Drug: 3 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 µg epinephrine applied into the test well
Trial: 33148261
Drug: e-Device (certolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-Device (certolizumab pegol self-injection)
Trial: 33148277
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin administration
Trial: 33148277
Drug: IS and
RxNorm normalized name: Poliomyelitis and tetanus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IS and hyperglycemia without treatment
Trial: 33148673
Drug: BMS-986178 monotherapy
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986178 monotherapy (20-320 mg)
Trial: 33148673
Drug: BMS-986178 plus
RxNorm normalized name: anti-OX40 antibody BMS 986178
DrugBank: anti-OX40 antibody BMS 986178 (DB15773)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986178 plus nivolumab (240-480 mg)
Trial: 33148673
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy (240-480 mg)
Trial: 33148673
Drug: BMS-986178 plus
RxNorm normalized name: anti-OX40 antibody BMS 986178
DrugBank: anti-OX40 antibody BMS 986178 (DB15773)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986178 plus ipilimumab (1-3 mg/kg)
Trial: 33148693
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four cycles then nivolumab 3 mg/kg every 2 weeks until progression or a maximum of 20 cycles.
Trial: 33150319
Drug: Psilocybin-assisted group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin-assisted group therapy (0.3-0.36 mg/kg po) with 8-10 group therapy visits and one psilocybin administration visit
Trial: 33150319
Drug: Psilocybin-assisted group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin-assisted group therapy
Trial: 33150320
Drug: Vi-DT vaccine
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-DT vaccine (one or two doses)
Trial: 33150320
Drug: Vi-DT vaccine
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-DT vaccine (two doses)
Trial: 33150325
Drug: Chewable mebendazole
RxNorm normalized name: mebendazole Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable mebendazole tablet
Trial: 33150325
Drug: Solid mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solid mebendazole tablet
Trial: 33150390
Drug: Lapatinib 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1250 mg/day for 6 months
Trial: 33150779
Drug: High-dose fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fish oil capsules
Trial: 33153503
Drug: Deep transcranial
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep transcranial magnetic stimulation (dTMS); specific dosage and duration not available
Trial: 33153629
Drug: lenzilumab 600
RxNorm normalized name: Lenzilumab
DrugBank: Lenzilumab (DB15148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenzilumab 600 mg intravenously for three doses
Trial: 33153727
Drug: Apararenone (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apararenone (320 mg on day 2, 20 mg/d on days 3-15) with Midazolam (2 mg on days 1 and 15)
Trial: 33153727
Drug: Apararenone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apararenone (40 mg/d on days 8-11, 10 mg/d on days 12-27) with Warfarin (25 mg on days 1 and 21)
Trial: 33153727
Drug: Apararenone (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apararenone (160 mg on day 11, 10 mg/d on days 12-28) with Digoxin (0.5 mg on days 1 and 24)
Trial: 33153960
Drug: OGTT (Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGTT (Oral Glucose Tolerance Test)
Trial: 33154057
Drug: nab-paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel plus gemcitabine (nab-P+Gem) chemotherapy plus split-course SBRT
Trial: 33154417
Drug: Faecal volatile
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faecal volatile organic compounds (VOCs) analysis
Trial: 33154953
Drug: Intranasal application
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal application of nan
Trial: 33155938
Drug: macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: macitentan 10 mg/day
Trial: 33155938
Drug: bosentan 250
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bosentan 250 mg/day
Trial: 33156244
Drug: Urine Drug
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine Drug Screen (UDS)
Trial: 33158819
Drug: Integrated intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated intervention (INT) which includes pharmacotherapy and a hybrid of behavioural support delivered by trained healthcare practitioners (HCPs) and a web-based application.
Trial: 33159216
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg IV weekly and Erlotinib 100 mg orally daily (RP2D)
Trial: 33159216
Drug: Temsirolimus 15
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 15 mg IV weekly and Erlotinib 100 mg orally daily (starting dose)
Trial: 33159216
Drug: Temsirolimus and
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus and Erlotinib combination
Trial: 33159365
Drug: Bisantrene (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisantrene (250 mg/m2)
Trial: 39675110
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist
Trial: 34861151
Drug: Background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background therapy
Trial: 33161013
Drug: FDG-PET-based dose-painting
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG-PET-based dose-painting technique with SIB-IMRT and concomitant Cisplatin after 2 cycles of induction chemotherapy.
Trial: 33161240
Drug: Emactuzumab (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emactuzumab (IV administration, 900 to 2000 mg every two weeks in dose-escalation phase, optimal biological dose of 1000 mg in dose-expansion phase)
Trial: 33161258
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant (Slim Modiolar) with bimodal stimulation (cochlear implant and hearing aid in contralateral ear) for 6-months postimplant
Trial: 33161258
Drug: Bimodal condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimodal condition (cochlear implant and hearing aid)
Trial: 33161777
Drug: Galvanic current-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galvanic current-induced vasodilation (CIV) in patients under low-dose aspirin (ASA; ≤ 500 mg/day)
Trial: 33161777
Drug: Galvanic current-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galvanic current-induced vasodilation (CIV) in patients not under low-dose aspirin (ASA; ≤ 500 mg/day)
Trial: 33163408
Drug: Ablation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablation therapy
Trial: 33164349
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg SC every 2 weeks (Q2W)
Trial: 33164349
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from IV to SC sarilumab 200 mg SC Q2W
Trial: 33164349
Drug: Continuing sarilumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing sarilumab 200 mg SC Q2W
Trial: 33164633
Drug: Age ≥65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age ≥65 years and use of diuretics at discharge
Trial: 33164985
Drug: Subcutaneous adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adipose tissue oxygen partial pressure (pO2) measurement in MHL, MHO, and MUO groups.
Trial: 33165001
Drug: Low-dose haemodialysis
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose haemodialysis
Trial: 33165001
Drug: Deintensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deintensification of haemodialysis treatment
Trial: 33165001
Drug: Standard-dose haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose haemodialysis
Trial: 33165755
Drug: Antivirals (67.6%)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antivirals (67.6%)
Trial: 33165773
Drug: Roxadustat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (100 mg single dose)
Trial: 33165773
Drug: Roxadustat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (100 mg single dose) after dialysis (P1)
Trial: 33165773
Drug: Roxadustat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (100 mg single dose) before dialysis (P2)
Trial: 33168363
Drug: Mediastinal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediastinal and subcutaneous adipose tissue
Trial: 33168612
Drug: Nifurtimox (NF)
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifurtimox (NF) treatment; children received 10 to 15 mg/kg/day for 60 to 90 days; adults received 8 to 10 mg/kg/day for 30 days
Trial: 33168818
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of unconjugated antibody with panitumumab-IRDye800CW
Trial: 33169671
Drug: Lung-protective ventilation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-protective ventilation with low tidal volume (median 6.3 mL/kg predicted bodyweight, IQR 5.7-7.1)
Trial: 33169671
Drug: Adjunctive treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive treatments for refractory hypoxaemia
Trial: 33170484
Drug: Pimasertib (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib (dose range 1-255 mg/day)
Trial: 33171487
Drug: Oral 5-azacytidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-azacytidine 300 mg once per day on days 1 to 14 and romidepsin 14 mg/m2 on days 8, 15, and 22 every 35 days
Trial: 33171487
Drug: Oral 5-azacytidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-azacytidine and romidepsin
Trial: 33172424
Drug: NTM-PD treatment
RxNorm normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-PD treatment (antibiotics)
Trial: 33172444
Drug: Multivariable prediction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivariable prediction model based on 8 variables (age, race, insurance, GINI income inequality, long-term anticoagulant use, receipt of a flu vaccine in the past year, frequency of missed clinic appointments, and clinic site)
Trial: 33172887
Drug: SARS-CoV-2 antibody
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibody testing
Trial: 33173161
Drug: Low-dose ruxolitinib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ruxolitinib plus steroid
Trial: 33173916
Drug: Centhaquine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centhaquine (0.01 mg/kg) in 100 mL normal saline infusion over 1 hour
Trial: 33173916
Drug: Control (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normal saline) in 100 mL infusion over 1 hour
Trial: 33176023
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid prescribing
Trial: 33176023
Drug: Treatment escalation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment escalation
Trial: 33176074
Drug: Subanesthetic intravenous
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic intravenous ketamine combined with prolonged exposure therapy
Trial: 33176443
Drug: Omecamtiv Mecarbil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv Mecarbil, dosage and duration not available
Trial: 33176617
Drug: Single-capsule bismuth
RxNorm normalized name: bismuth subsalicylate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-capsule bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline, metronidazole), 3 capsules every 6 hours for 10 days
Trial: 33176617
Drug: Single-capsule bismuth
RxNorm normalized name: bismuth subsalicylate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-capsule bismuth quadruple therapy (first-line treatment)
Trial: 33176617
Drug: Single-capsule bismuth
RxNorm normalized name: bismuth subsalicylate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-capsule bismuth quadruple therapy (second-line treatment)
Trial: 33176617
Drug: Single-capsule bismuth
RxNorm normalized name: bismuth subsalicylate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-capsule bismuth quadruple therapy (third to sixth line treatment)
Trial: 33176617
Drug: Single-capsule bismuth
RxNorm normalized name: bismuth subsalicylate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-capsule bismuth quadruple therapy
Trial: 33178636
Drug: E6011 (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 (humanized anti-FKN monoclonal antibody)
Trial: 33179591
Drug: Solriamfetol 75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 75, 150, or 300 mg/day for ≤ 52 weeks
Trial: 33179845
Drug: Long-acting glucagon-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting glucagon-like peptide-1 receptor agonists (LA GLP-1RAs)
Trial: 33180026
Drug: Psychotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy alone (treatment-as-usual)
Trial: 33180106
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of TKIs
Trial: 33181832
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ibrutinib, obinutuzumab, and venetoclax (venetoclax at 400 mg per day).
Trial: 33181832
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ibrutinib, obinutuzumab, and venetoclax.
Trial: 33183506
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment impact during the pandemic
Trial: 33184050
Drug: RhoC-derived 20mer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhoC-derived 20mer peptide vaccine (0.1 mg, subcutaneous injections every 2 weeks for the first 6 doses, then every 4 weeks for a total of 30 weeks)
Trial: 33184050
Drug: RhoC-derived 20mer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhoC-derived 20mer peptide vaccine
Trial: 33185490
Drug: Temporoparietal fascia
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporoparietal fascia over polypropylene implants
Trial: 33186237
Drug: Edoxaban administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban administered via PEG
Trial: 33186617
Drug: Combined external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined external beam radiation therapy (45 Gy in 25 fractions) and HDR brachytherapy (19 Gy in 2 fractions)
Trial: 33186617
Drug: Combined external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined external beam radiation therapy and HDR brachytherapy
Trial: 33187482
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (150-200 µg daily) during preconception, pregnancy, and lactation
Trial: 33187482
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (150-200 µg daily)
Trial: 33187482
Drug: Serum thyroid-hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum thyroid-hormone parameters in the 1st trimester of pregnancy
Trial: 33188385
Drug: Azlocillin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azlocillin (100 mg/kg q8h)
Trial: 33188413
Drug: Mode of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mode of delivery (C-section) with antibiotic exposure
Trial: 33188873
Drug: Adjuvant gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant gemcitabine treatment (43 patients in monocentric cohort, 203 patients in multicentric cohort)